Zenas BioPharma, Inc. (ZBIO) financial statements and ratios from SEC XBRL: revenue $10.00M (latest fiscal year), net margin -3777.4%, revenue growth -69.8% YoY. Income statement, balance sheet, cash flow, and valuation. First-party data.
| Revenue (latest FY) | $10.00M |
| Net Margin | -3777.4% |
| Return on Equity | -196.0% |
| Current Ratio | 9.93 |
| Net Debt / EBITDA | 0.1 |
| Revenue Growth (YoY) | -69.8% |
| EPS Growth (YoY) | 82.5% |
| FCF Growth (YoY) | 102.9% |
| Price / Book | 7.96 |
| Price / Sales | 489.29 |
| FCF Yield | -8.8% |
| Altman Z-Score | 2.42 (grey) |
| Industry P/E (Pharmaceutical Products) | 15.1 |
| Sector P/E (Healthcare) | 19.4 |
ZBIO overview · ZBIO earnings · ZBIO KPIs · ZBIO documents · ZBIO ownership · ZBIO peers
Data sourced from U.S. SEC EDGAR XBRL filings. Not personalized investment advice.